关键词二 优服务 核心提示 省十四届人大五次会议代表口中的高频词是啥？营商环境！ 会场上、审议中，营商环境被代表们频频提及，大家讲经历、谈感受、提建议，对体现重视程度 的"坚持把优化营商环境作为发展的生命线"竖起大拇指，对"推动全省营商环境在短期内实现明显好 转、根本好转"的决心投下信任票。 从三个关键词中，人们越来越体会到，各类经营主体正在经历辽宁的营商之变！ 关键词一 讲诚信 常态化开展政府履约践诺专项整治，以政府诚信引领社会诚信，在代表们眼中，政府工作报告的这 一表述字字如金！ 解从阁代表切身感受到了政府主动"理旧账"的诚信："企业经营，最忌历史遗留问题悬而未决。现 在，市、区主要领导深入企业，不仅牵头成立专班务实推进，更建立了'保姆式'、24小时响应的服务机 制，让我们真切感受到了政府重视诚信、呵护市场的决心。"营商环境的冷暖，企业家心中有本明账。 解从阁表示，集团已正式决定，全力投入营口"沈阳TIR国际公路运输附属区"项目建设。 从中可见，诚信就是吸引力，营商环境就是生产力！ "项目落地不是项目的结束，而是开始。咱们把企业招来，后续企业遇到任何问题，都可以找我 们。"杨东一代表一直在基层从事招商服务 ...

【今日头条】 23年来首次全面修订 《药品管理法实施条例》将于5月15日施行 国务院总理李强日前签署国务院令，公布修订后的《中华人民共和国药品管理法实施条例》，自2026年 5月15日起施行。《条例》共9章89条，修订后的主要内容如下。 一是完善药品研制和注册制度。支持以临床价值为导向的药品研制和创新，鼓励研究和创制新药，支持 新药临床推广和使用。明确药物非临床安全性评价研究机构资格认定程序，细化药物临床试验管理要 求。设立药品上市注册加快程序，明确药品再注册程序，规定处方药、非处方药转换机制。对符合条件 的儿童用药品、罕见病治疗用药品给予市场独占期，对含有新型化学成份的药品等进行数据保护。细化 药品上市许可持有人的责任。 二是加强药品生产管理。严格药品委托生产管理，压实委托生产时药品上市许可持有人的责任，明确可 以委托分段生产药品的情形。明确中药饮片、中药配方颗粒生产、销售的管理要求。 三是规范药品经营和使用。完善药品网络销售管理制度，压实药品网络交易第三方平台提供者责任。加 强医疗机构药事管理，保障使用环节药品质量。明确医疗机构配制制剂审批流程，规定医疗机构制剂调 剂使用条件和程序，支持配制儿童用医疗机构 ...

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. anticipates a significant increase in net profit for the year 2025, while also forecasting a substantial decrease in net profit after excluding non-recurring gains [2][4]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of approximately 460 million yuan for the year 2025, representing an increase of about 352.01 million yuan, or 325.97% compared to the previous year [2][4]. - The forecasted net profit attributable to shareholders after excluding non-recurring gains is approximately -215 million yuan, indicating a decrease of about 311.62 million yuan, or 322.53% year-on-year [2][4]. Group 2: Previous Year Performance - In the previous year, the total profit was approximately 201.20 million yuan, with a net profit attributable to shareholders of about 107.99 million yuan, and a net profit after excluding non-recurring gains of approximately 96.62 million yuan [6]. Group 3: Reasons for Performance Changes - The significant increase in net profit is primarily due to the equity method accounting for Tian Shili Biological Pharmaceutical Industry Group Co., Ltd., which sold its equity assets, resulting in substantial non-recurring gains [8]. - The decrease in net profit after excluding non-recurring gains is attributed to reduced demand in the cement industry and declining prices and sales in the pharmaceutical sector, influenced by policies such as drug procurement and price reductions [9][10].

Core Viewpoint - *ST San Sheng (002742.SZ) expects a net profit attributable to shareholders of the listed company to be between -530 million and -380 million yuan for 2025, with an operating income projected between 910 million and 1.07 billion yuan [1] Group 1: Financial Performance - The construction materials and pharmaceutical sectors experienced varying degrees of decline due to tight funding and changes in the external market environment [1] - The net profit after deducting non-recurring gains and losses is expected to be between -520 million and -360 million yuan [1] - The company's operating revenue is forecasted to be between 910 million and 1.07 billion yuan [1] Group 2: Debt and Liabilities - The company's restructuring plan does not exempt subsidiaries from joint liability guarantees for their borrowings, and related debts will be handled according to the restructuring plan [1] - The company has recognized estimated liabilities for potential guarantee losses based on the prudence principle of accounting standards [1] Group 3: Asset Impairment - The company has made provisions for impairment losses on assets based on the actual operating conditions of the pharmaceutical company and changes in the industry market [1]

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to engage in long-term collaboration on CDMO projects, enhancing its competitive edge in the CDMO business [1]. Group 1 - The strategic cooperation agreement establishes a partnership based on mutual benefits and complementary advantages between Pro Pharmaceutical and Derui Zhiyao [1]. - The collaboration aims to promote the application of relevant technologies in Pro Pharmaceutical's CDMO projects, from process development to large-scale production [1]. - This partnership is expected to facilitate the expansion of Pro Pharmaceutical's CDMO business, thereby improving its competitiveness in the industry [1].

Market Overview - The Hang Seng Index rose by 0.1%, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 0.2% and 1.2%, respectively[1] - International oil and gold prices surged, driven by geopolitical tensions and supply concerns, leading to gains in leading oil and gold stocks[1] - The latest CCL index reported at 145.54, a weekly increase of 0.63%, indicating a recovery in Hong Kong residential prices[1] Economic Indicators - The U.S. durable goods orders for November increased by 5.3%, surpassing Bloomberg's forecast of 3.1% and the previous value of -2.1%[3] - In China, the transaction volume of new homes in 30 major cities reached 1.19 million square meters, a year-on-year decline of 32.3%[3] Sector Performance - The pharmaceutical sector saw most stocks decline, while Junshi Biosciences (1877 HK) rose due to concerns over Nipah virus infections in India[4] - The automotive sector experienced a decline, with January retail sales expected to be around 1.8 million units, a month-on-month decrease of 20.4%[5] - Gold prices reached a new high, surpassing $5,000 per ounce, boosting demand for gold products and leading to gains in related stocks[5]

Core Insights - Beijing has made significant progress in promoting the application of innovative medical devices and the integration of "artificial intelligence + healthcare" [1] - There are challenges in bringing innovative medical products to the clinical "last mile," particularly for certain diseases [1] Group 1: AI in Prenatal Diagnosis - The accuracy of prenatal diagnosis for congenital defects is currently between 30% and 60%, highlighting the need for improved diagnostic methods [4] - AI technology is expected to enhance the accuracy and accessibility of prenatal diagnosis by training models on extensive ultrasound data [4] - AI can assist in planning optimal intervention paths during ultrasound-guided procedures, thereby improving safety and effectiveness [4] Group 2: Strengthening Grassroots Healthcare - The grassroots healthcare system is crucial for providing accessible health services, yet there are deficiencies in diagnostic capabilities at this level [5] - AI-assisted prenatal ultrasound diagnostic systems could significantly increase diagnostic accuracy to over 95% [5] - There is a call for dedicated funding to support AI innovations in maternal and child health [5] Group 3: Challenges in Clinical Application of Innovative Products - Recent advancements in minimally invasive surgical techniques for newborns have been noted, but there are hurdles in clinical application due to complex regulatory pathways [7] - The approval process for products that combine medical devices and biological agents is complicated, necessitating clearer clinical translation guidance [7] - A recommendation has been made to create a more flexible access and procurement channel for innovative domestic medical devices aimed at special populations [7]

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for the year 2025, while the net profit excluding non-recurring gains and losses is projected to decrease substantially [1][2]. Group 1: Financial Projections - The company anticipates achieving a net profit of approximately 460 million yuan for the year 2025, which represents an increase of about 352 million yuan, or a growth of approximately 325.97% compared to the previous year [1]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be around -21.5 million yuan, indicating a decrease of about 31.2 million yuan, or a decline of approximately 322.53% year-on-year [1]. Group 2: Reasons for Performance Changes - The significant increase in net profit is primarily due to the equity method accounting for the joint venture Tian Shili Biological Pharmaceutical Industry Group Co., Ltd., which sold its equity assets, resulting in substantial profit growth from non-recurring gains [2]. - The company has been actively implementing energy-saving and consumption-reduction modifications and strictly controlling product costs; however, the prices and sales volumes of cement and clinker products have decreased year-on-year [2]. - The pharmaceutical segment has faced challenges due to policies such as drug procurement and price reductions, as well as a continuous decline in pesticide market prices, leading to decreased prices and sales volumes of major products [2]. - The company’s subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has terminated the clinical trial and subsequent development of the injectable deoxynojirimycin project, resulting in a full impairment provision of 18.2141 million yuan for the development costs, which will reduce the total profit for 2025 [2].

Core Viewpoint - Fujian Pharmaceutical is experiencing significant operational improvement in 2025, driven primarily by its lithium battery electrolyte additive business, which has benefited from rising demand in the power battery and energy storage markets [1][5]. Group 1: Business Performance - The lithium battery electrolyte additive products, such as VC and FEC, saw a substantial price increase in Q4 2025, with battery-grade VC averaging 164,000 yuan/ton, up over 200% from the low in September [1]. - The pharmaceutical manufacturing segment has optimized steadily despite intense market competition, with a decrease in the price of key raw materials like 6-APA, leading to an improvement in gross margins [1][2]. - The company reported a net loss of 39 million to 57 million yuan for the year, marking a significant reduction in losses, and achieved profitability in Q4, indicating a positive trend in operational performance [5]. Group 2: Future Outlook - The synthetic biological microbial protein business achieved critical breakthroughs in 2025, obtaining multiple certifications that pave the way for large-scale production, although its contribution to 2025's performance is limited [3]. - For 2026, the company plans to consolidate its market position in pharmaceuticals, leverage price increases in the new energy sector, and accelerate the development of the microbial protein project to enhance capacity and market presence [3].

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is experiencing mixed performance in the A-share market, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%, and the Shenzhen Component Index at 14316.64 points, down 0.85% [1][1] - The Shenwan Pharmaceutical Industry Index closed at 8648.35 points, up 0.29%, while the Hang Seng Healthcare Index in Hong Kong closed at 4032.36 points, down 1.58% [1][1] Company-Specific Insights Performance Forecasts - **Guangji Pharmaceutical**: Expected net loss for 2025 is between 518 million to 399 million yuan, a significant increase from the previous year's loss of 295 million yuan [2][2] - **Yixin Pharmacy**: Projected net profit for 2025 is between 260 million to 330 million yuan, a substantial increase of 127.79% to 189.12% year-on-year [2][3] - **International Medicine**: Anticipated revenue drop to 4.06 billion to 4.08 billion yuan, a 15.7% decline, with net loss expected to widen to between 315 million to 295 million yuan [3][3] - **Weichip Bio**: Expected revenue of 910 million yuan, a 38.32% increase, with net profit turning positive at 53.46 million yuan, a significant improvement from a loss of 115 million yuan [3][3] - **Tonghua Dongbao**: Forecasted net profit of 1.242 billion yuan, recovering from a loss of 42.72 million yuan in the previous year [4][4] - **Meinuo Pharma**: Expected net profit between 100 million to 123 million yuan, a growth of 49.69% to 84.11% year-on-year [4][4] - **Sangfor Biopharma**: Projected revenue of 4.2 billion yuan, a significant increase of 251.76%, with net profit expected to reach 2.9 billion yuan, a 311.35% increase [4][5] - **Huahai Pharmaceutical**: Expected net profit to decline by 70% to 80%, with projections between 224 million to 335 million yuan [5][5] - **Dabo Medical**: Anticipated net profit between 580 million to 610 million yuan, a growth of 62.55% to 70.96% [5][5] Regulatory Approvals - **Hengrui Medicine**: Received clinical trial approval for SHR-1049 injection [2][2] - **Qianjin Pharmaceutical**: Obtained drug registration for aluminum magnesium carbonate chewable tablets [2][2] - **Wantai Bio**: Two-valent HPV vaccine passed WHO PQ periodic review [2][2] Market Trends - The A-share market shows volatility with significant fluctuations in stock performance, particularly in the pharmaceutical sector, indicating potential investment opportunities and risks [1][1] - The performance of individual companies varies widely, with some showing strong growth while others face significant losses, highlighting the need for careful analysis when considering investments in this sector [2][3][4][5]